1. Diverse Galactooligosaccharides Differentially Reduce LPS-Induced Inflammation in Macrophages
   Congcong Sun et al, 2022, Foods CrossRef
2. Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells
   Jin-Mei Yao et al, 2023, Free Radical Biology and Medicine CrossRef
3. Akkermansia muciniphila - A Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease
   Goutam Banerjee et al, 2024, Current Pharmaceutical Biotechnology CrossRef
4. Collinsella aerofaciens linked with increased ethanol production and liver inflammation contribute to the pathophysiology of NAFLD
   Ayushi Purohit et al, 2024, iScience CrossRef
5. Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
   Wasitha P. D. W. Thilakarathna et al, 2024, Molecules CrossRef
6. Differences in Fecal Short-Chain Fatty Acids between Alcoholic Fatty Liver-Induced Cirrhosis and Non-alcoholic (Metabolic-Associated) Fatty Liver-Induced Cirrhosis
   Xinlu Cao et al, 2023, Metabolites CrossRef
7. Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
   Salvatore Pezzino et al, 2022, Biology CrossRef
8. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
   Muthukumaran Jayachandran et al, 2023, Reviews in Endocrine and Metabolic Disorders CrossRef
9. Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
   Chunye Zhang et al, 2023, Exploration of Digestive Diseases CrossRef
10. Preventive mechanisms of Chinese Tibetan medicine Triphala against nonalcoholic fatty liver disease
    Yan Jiang et al, 2024, Phytomedicine CrossRef
11. Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
    Mira Thing et al, 2024, BMC Gastroenterology CrossRef
12. Current Status of Research on Cardiovascular Risk in Patients with Non-Alcoholic Fatty Liver Disease
    ·巴哈提 娜迪热, 2023, Advances in Clinical Medicine CrossRef
13. What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
    Giovanni Tarantino et al, 2024, Lipids in Health and Disease CrossRef